Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo.
about
Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutionsAdenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemiaOral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- miceResolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction.A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model.Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly.Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.Purinergic receptors in gastrointestinal inflammation.IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.A2A adenosine receptor protects tumors from antitumor T cells.Acute adenosinergic cardioprotection in ischemic-reperfused hearts.Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors.Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells.Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias.Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Rebuilding immunity in cancer patients.The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation.Anti-inflammatory effects of inosine in allergic lung inflammation in mice: evidence for the participation of adenosine A2A and A 3 receptorsDiminished iron concentrations increase adenosine A(2A) receptor levels in mouse striatum and cultured human neuroblastoma cells.Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway.The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells.Pleural fluid from tuberculous pleurisy inhibits the functions of T cells and the differentiation of Th1 cells via immunosuppressive factors.Role of peripheral nerve fibres in acute and chronic inflammation in arthritis.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis.A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases.Adenosine and IFN-{alpha} synergistically increase IFN-gamma production of human NK cells.Tissue-resident ecto-5' nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain.Adenosine and lymphocyte regulation.From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy.P1 receptors and cytokine secretion.Macrophage A2A Adenosine Receptors Are Essential to Protect from Progressive Kidney InjuryInhibition of small HA fragment activity and stimulation of A2A adenosine receptor pathway limit apoptosis and reduce cartilage damage in experimental arthritis.
P2860
Q24644038-09D4B7C6-8A3E-4400-A91F-C80B5CC2B12AQ26851322-31DE6C23-E2F2-456C-86CA-7B36F7BAAA8BQ28476642-69CE9D96-BCF5-4156-B1F4-4EFE50C2D2B2Q30437086-0D1F1FD6-B604-471E-B428-01670CAAE407Q30440124-F37D7041-88A3-4A7E-BEFD-D019A8B56E87Q30440525-4F484A0E-895C-4077-A05A-A5EC0650E9D1Q30987183-884B701D-7F6D-4861-B7F1-5FC42DFCEE20Q33521778-B7CF9347-271D-4058-BC77-3A1B41FF2440Q33616120-E647A961-56CA-42AE-97B0-B4675B54B2EFQ33748026-FE5E7F78-A347-4960-A11B-4CE0AC5F3B73Q34008598-3B8A4D3B-4A76-4C2E-9EDA-9A6981FCBEC0Q34760267-FFA9BEA3-F89C-4283-81B7-2D22D2BBD525Q35016529-E63CDC3E-5D98-438F-AF7F-83D80C8AE2E9Q35560907-41F1F1EF-CEFC-4873-B221-B201594E48C2Q36301576-5AF6BC47-D017-4C6A-BDD3-9B5B1DF5E501Q36362887-BF80ED0A-9AE4-4099-9C7D-FE45D2A75858Q36496998-EFB664F4-C513-4443-B980-E4BECA7FD69FQ36620552-06901494-BB85-4FDF-9DFE-EDCEF5FA6772Q36784329-1329F1A2-DC14-4115-B62C-D564644D9893Q36804999-8B6268F9-B7D8-415A-AD2F-FAEABAB48D69Q36821572-5691C0D8-882B-4330-8D94-D36FF6B17E43Q36934947-E7342F23-5805-48BE-B9D9-129F1DC0E2DFQ36993161-CCC885EB-DC7D-4C9E-8F9C-6D2E69ABD1AAQ37131959-820344D9-84B9-4290-9734-661FAA97668FQ37443943-A476ED71-C9B3-4C49-978F-F06032A65084Q37444438-99A0D603-266A-4792-B926-ECBF815D0843Q37535392-DE3C6CC6-DC7F-4AA6-93E9-140BE1EB3EEEQ37729535-3EE79475-E3AE-4C21-86F6-C0CC4C2F8834Q38059456-D0A6043F-9A12-46A7-8385-46DC45F2A1E5Q38636569-1F754F82-C966-4C1D-B68E-A40AD1894E23Q38767477-1EB1A3CD-F7E1-4BDB-858D-92A23CB5627EQ38900954-917E1848-3DF9-4A02-9FD9-8D84D5C61350Q39157059-407FD89F-F208-4A31-8582-5CF3801E17B9Q40017179-97088E55-C847-4FEB-9ED1-E2572BC2361DQ40418538-D8438062-8E38-495D-ADC0-906E746E6293Q40729772-7B891055-2A11-4414-A5B3-67162FBBBD1CQ40729839-B65373D9-ED30-4959-BC62-24F65F726D7DQ40730075-027B1F21-3501-4EBE-96A0-58F909A5AFF8Q41630185-F02AEC29-290D-437F-A9DA-EB29AD4648B6Q41685843-693E420E-370B-4058-A8A6-303E4D08C82E
P2860
Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@ast
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@en
type
label
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@ast
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@en
prefLabel
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@ast
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@en
P1476
Use of the A(2A) adenosine rec ...... engineer inflammation in vivo.
@en
P2093
Michail V Sitkovsky
P304
P356
10.1016/S0006-2952(02)01548-4
P407
P577
2003-02-01T00:00:00Z